AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12741340 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual administration of Sildenafil citrate (crushed and dissolved under the tongue) 15 minutes before planned sexual relations
Number of subjects: 30
Study 12741340 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of Sildenafil citrate (50-100 mg) 30 minutes before planned sexual relations
Number of subjects: 30
Study 10800431 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief intervention (9-minute video, 12 to 15 minutes of behavioral counseling, clinician advice to quit, follow-up telephone calls)
Number of subjects: 1154
Study 10800431 — intervention group
Group type: COMPARATOR
Intervention: Advice only (control group)
Number of subjects: 1154
Study 10800431 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief intervention
Number of subjects: 1154
Study 8618764 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretreatment with one drop of diclofenac sodium 0.1% four times per day for 3 days before surgery plus one drop of diclofenac sodium 0.1% every 15 minutes for four doses, beginning 1 hour before surgery.
Number of subjects: 60
Study 8618764 — intervention group
Group type: COMPARATOR
Intervention: No pretreatment, but one drop of diclofenac sodium 0.1% every 15 minutes for four doses beginning 1 hour before surgery.
Number of subjects: 60
Study 8618764 — intervention group
Group type: COMPARATOR
Intervention: No diclofenac sodium drops at all before surgery.
Number of subjects: 60
Study 1598878 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler valve area measurement before and after aortic balloon valvuloplasty
Number of subjects: 1197
Study 1598878 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive valve area measurement before and after aortic balloon valvuloplasty
Number of subjects: 1197
Study 1598878 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler valve area measurement before and after mitral balloon valvuloplasty
Number of subjects: 1197
Study 1598878 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive valve area measurement before and after mitral balloon valvuloplasty
Number of subjects: 1197
Study 6377118 — intervention group
Group type: EXPERIMENTAL
Intervention: iohexol 300 mg I/ml
Number of subjects: 54
Study 6377118 — intervention group
Group type: COMPARATOR
Intervention: Hexabrix 320 mg I/ml
Number of subjects: 54
Study 30144264 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured self-monitoring of blood glucose (SMBG)
Number of subjects: 250
Study 30144264 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 250
Study 29494371 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive‐educational nurse‐led intervention
Number of subjects: 160
Study 29494371 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 160
Study 27362551 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter hepatic arterial chemoembolization (group A)
Number of subjects: 50
Study 27362551 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency thermal ablation combined with transcatheter arterial chemoembolization (group B)
Number of subjects: 50
Study 27362551 — intervention group
Group type: EXPERIMENTAL
Intervention: Microwave ablation combined with transcatheter arterial chemoembolization (group C)
Number of subjects: 50
Study 24555511 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentalization Based Therapy for Eating Disorders (MBT-ED)
Number of subjects: 0
Study 24555511 — intervention group
Group type: COMPARATOR
Intervention: Specialist Supportive Clinical Management (SSCM-ED)
Number of subjects: 0
Study 22314329 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative FOLFOX chemotherapy
Number of subjects: 342
Study 22314329 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 342
Study 20190349 — intervention group
Group type: COMPARATOR
Intervention: Glucose solution (50 g glucose)
Number of subjects: 20
Study 20190349 — intervention group
Group type: COMPARATOR
Intervention: Griffin's Fruitli bar (50 g available carbohydrate)
Number of subjects: 20
Study 20190349 — intervention group
Group type: COMPARATOR
Intervention: Peak Fuel's Summit bar (50 g available carbohydrate)
Number of subjects: 20
Study 18059578 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-test carbohydrate ingestion (CHO, 2x300 mL, 7% solution)
Number of subjects: 15
Study 18059578 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Pl) ingestion
Number of subjects: 15
Study 18059578 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-test carbohydrate ingestion (CHO)
Number of subjects: 15
Study 18059578 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Pl)
Number of subjects: 15
Study 15012171 — intervention group
Group type: COMPARATOR
Intervention: Pioglitazone 30 mg/day
Number of subjects: 270
Study 15012171 — intervention group
Group type: COMPARATOR
Intervention: Pioglitazone 7.5/15/30 mg/day or 15/30/45 mg/day
Number of subjects: 270
Study 15012171 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone added to sulfonylurea
Number of subjects: 270
Study 15012171 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone added to metformin
Number of subjects: 270
Study 15012171 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone added to insulin
Number of subjects: 270
Study 15012171 — intervention group
Group type: COMPARATOR
Intervention: Pioglitazone monotherapy
Number of subjects: 270
Study 15012171 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone combined with sulfonylurea
Number of subjects: 270
Study 15012171 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone combined with metformin
Number of subjects: 270
Study 15012171 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone combined with insulin
Number of subjects: 270
Study 11666121 — intervention group
Group type: EXPERIMENTAL
Intervention: TTFCA 60 mg thrice daily for 2 days before the flight, the day of the flight, and for another day after the flight
Number of subjects: 0
Study 11666121 — intervention group
Group type: COMPARATOR
Intervention: Control group (no drug or other treatment)
Number of subjects: 0
Study 9733274 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia (PCA) with intravenous diamorphine
Number of subjects: 65
Study 9733274 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion (CI) with intravenous diamorphine
Number of subjects: 65
Study 8061476 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-retirement planning intervention
Number of subjects: 75
Study 8061476 — intervention group
Group type: COMPARATOR
Intervention: Control group (age peers)
Number of subjects: 75
Study 2923765 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% enflurane
Number of subjects: 113
Study 2923765 — intervention group
Group type: COMPARATOR
Intervention: 1.25% isoflurane
Number of subjects: 113
Study 31568288 — intervention group
Group type: EXPERIMENTAL
Intervention: Large-gel-particle hyaluronic acid with 0.3% lidocaine, 20 mg/ml
Number of subjects: 90
Study 31568288 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 90
Study 28940301 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibetan yoga program (TYP)
Number of subjects: 227
Study 28940301 — intervention group
Group type: COMPARATOR
Intervention: Stretching program (STP)
Number of subjects: 227
Study 26818364 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% sucrose solution
Number of subjects: 114
Study 26818364 — intervention group
Group type: COMPARATOR
Intervention: Placebo (water)
Number of subjects: 114
Study 24819671 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated cigarette (HC)
Number of subjects: 70
Study 24819671 — intervention group
Group type: COMPARATOR
Intervention: Conventional cigarette (CC10)
Number of subjects: 70
Study 21470389 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher systolic blood pressure (SBP) ≥160 mmHg
Number of subjects: 711
Study 21470389 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index (BMI) ≥30
Number of subjects: 711
Study 21470389 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinopathy prevalence
Number of subjects: 711
Study 21470389 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension and obesity
Number of subjects: 711
Study 21470389 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term, short-term or current glycaemia
Number of subjects: 711
Study 20712499 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based self-administered program
Number of subjects: 127
Study 20712499 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-applied program
Number of subjects: 127
Study 20712499 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 127
Study 17703152 — intervention group
Group type: EXPERIMENTAL
Intervention: Aldehyde test (AT)
Number of subjects: 150
Study 15890106 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative adjuvant chemotherapy
Number of subjects: 6518
Study 15890106 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 6518
Study 12476093 — intervention group
Group type: EXPERIMENTAL
Intervention: Verteporfin therapy (6 mg/m² body surface area)
Number of subjects: 47
Study 12476093 — intervention group
Group type: EXPERIMENTAL
Intervention: Verteporfin therapy (6 to 20 mg/m²)
Number of subjects: 47
Study 12476093 — intervention group
Group type: EXPERIMENTAL
Intervention: Verteporfin therapy
Number of subjects: 47
Study 10423707 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-30 mmol/day of oral magnesium hydroxide
Number of subjects: 28
Study 10423707 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 28
Study 7498228 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc-HMPAO labelled leucocytes
Number of subjects: 27
Study 7498228 — intervention group
Group type: EXPERIMENTAL
Intervention: 111In-human immunoglobulin (IgG)
Number of subjects: 27
Study 7498228 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both agents
Number of subjects: 27
Study 2252453 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine treatment
Number of subjects: 0
Study 2252453 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 0
Study 2252453 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with progressive supranuclear palsy
Number of subjects: 0
Study 6773843 — intervention group
Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate (1.2 g/day)
Number of subjects: 18
Study 6773843 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 31065881 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily partner‐focused petitionary prayer (PFPP)
Number of subjects: 90
Study 31065881 — intervention group
Group type: COMPARATOR
Intervention: Waitlist
Number of subjects: 90
Study 31065881 — intervention group
Group type: COMPARATOR
Intervention: Meditation
Number of subjects: 90
Study 30689020 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter-defibrillator (ICD) therapy
Number of subjects: 1676
Study 30689020 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1676
Study 28670407 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary group-based intervention (physiotherapy educational program + health educational program)
Number of subjects: 136
Study 28670407 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary group-based intervention
Number of subjects: 136
Study 28670407 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy educational program (control group)
Number of subjects: 136
Study 25714044 — intervention group
Group type: EXPERIMENTAL
Intervention: Gardasil (qHPV) booster dose
Number of subjects: 366
Study 25714044 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervarix (bHPV) booster dose
Number of subjects: 366
Study 25406682 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with house-dust mite or grass pollen; applied for 2 years after a dose-up phase.
Number of subjects: 31
Study 25406682 — intervention group
Group type: COMPARATOR
Intervention: Placebo; applied for 2 years after a dose-up phase.
Number of subjects: 31
Study 22337568 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib 120 mg preoperatively
Number of subjects: 11
Study 22337568 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 19455286 — intervention group
Group type: EXPERIMENTAL
Intervention: Open appendectomy (OA)
Number of subjects: 130000
Study 19455286 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic appendectomy (LA)
Number of subjects: 130000
Study 19455286 — intervention group
Group type: EXPERIMENTAL
Intervention: Open appendectomy (OA) and Laparoscopic appendectomy (LA)
Number of subjects: 130000
Study 17822463 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim (200 mg)
Number of subjects: 2481
Study 17822463 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (500 mg)
Number of subjects: 2481
Study 17822463 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2481
Study 14734464 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib treatment (median duration of 13 months)
Number of subjects: 100
Study 14734464 — intervention group
Group type: EXPERIMENTAL
Intervention: Genomic profile of response based on 31 identified genes
Number of subjects: 100
Study 11964590 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (0.05 mg/kg bolus + 0.2 mg/kg infusion over 40 min)
Number of subjects: 32
Study 11964590 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (1 mg/kg bolus + 4 mg/kg infusion)
Number of subjects: 32
Study 11964590 — intervention group
Group type: COMPARATOR
Intervention: Active placebo (Diphenhydramine 10 mg bolus + 40 mg infusion)
Number of subjects: 32
Study 9579445 — intervention group
Group type: EXPERIMENTAL
Intervention: dl-norgestrel (0.05 mg/day)
Number of subjects: 9
Study 9579445 — intervention group
Group type: EXPERIMENTAL
Intervention: medroxyprogesterone acetate (2.5 mg/day)
Number of subjects: 9
Study 7623904 — intervention group
Group type: EXPERIMENTAL
Intervention: Sclerotherapy with octreotide (25 micrograms per hour for five days)
Number of subjects: 199
Study 7623904 — intervention group
Group type: COMPARATOR
Intervention: Sclerotherapy alone (placebo)
Number of subjects: 199
Study 7623904 — intervention group
Group type: EXPERIMENTAL
Intervention: Sclerotherapy with octreotide
Number of subjects: 199
Study 2633927 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine tablets (A)
Number of subjects: 12
Study 2633927 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine oral solution (B)
Number of subjects: 12
Study 7377746 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadiazine (SD) 4 mg/kg twice a day, loading dose 8 mg/kg
Number of subjects: 0
Study 7377746 — intervention group
Group type: COMPARATOR
Intervention: Fulfafurazole (SF) 50 mg/kg four times a day
Number of subjects: 0
Study 30945088 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal fluid strategy (12 ml/kg/h)
Number of subjects: 86
Study 30945088 — intervention group
Group type: COMPARATOR
Intervention: Restricted fluid strategy (4 ml/kg/h)
Number of subjects: 86
Study 30945088 — intervention group
Group type: COMPARATOR
Intervention: Goal-directed (GD) fluid replacement using stroke volume variation (SVV)
Number of subjects: 86
Study 31402192 — intervention group
Group type: EXPERIMENTAL
Intervention: Retromandibular transparotid approach
Number of subjects: 30
Study 31402192 — intervention group
Group type: COMPARATOR
Intervention: Retromandibular TMAP approach
Number of subjects: 30
Study 25829263 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational booklet on anticoagulant treatment with warfarin
Number of subjects: 235
Study 25829263 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 235
Study 23661293 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent oxaliplatin 70 mg/m² weekly for six cycles
Number of subjects: 115
Study 23661293 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (RT) alone
Number of subjects: 115
Study 17643621 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial artery
Number of subjects: 394
Study 17643621 — intervention group
Group type: COMPARATOR
Intervention: Free right internal thoracic artery
Number of subjects: 394
Study 15242248 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatase inhibitors
Number of subjects: 0
Study 10989730 — intervention group
Group type: EXPERIMENTAL
Intervention: diltiazem 300 mg/daily
Number of subjects: 14
Study 10989730 — intervention group
Group type: COMPARATOR
Intervention: amlodipine 10 mg/daily
Number of subjects: 14
Study 9238883 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentifrice containing 0.3% triclosan and 2.0% PVM/MA copolymer in a 0.243% NaF/silica (1100 ppm F) base
Number of subjects: 1542
Study 9238883 — intervention group
Group type: COMPARATOR
Intervention: Dentifrice containing 0.243% NaF/silica (1100 ppm F) without triclosan and copolymer
Number of subjects: 1542
Study 1285740 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant cisplatin-based chemotherapy (n = 97)
Number of subjects: 180
Study 1285740 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy for recurrent disease (n = 83)
Number of subjects: 180
Study 1285740 — intervention group
Group type: COMPARATOR
Intervention: Observation group (control group)
Number of subjects: 180
Study 1285740 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant treatment group (control group)
Number of subjects: 180
Study 1285740 — intervention group
Group type: EXPERIMENTAL
Intervention: Both chemotherapy groups (adjuvant and recurrent)
Number of subjects: 180
Study 1285740 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 180
Study 3934402 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.2 g protein/kg/day
Number of subjects: 21
Study 3934402 — intervention group
Group type: COMPARATOR
Intervention: 1.5 g protein/kg/day
Number of subjects: 21
Study 31133361 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-slide PowerPoint instruction on nasal analysis
Number of subjects: 20
Study 31133361 — intervention group
Group type: COMPARATOR
Intervention: Standard sequence of photographs for assessment
Number of subjects: 20
Study 28817334 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Health Worker (CHW) intervention
Number of subjects: 302
Study 28817334 — intervention group
Group type: COMPARATOR
Intervention: Goal-setting alone (Control)
Number of subjects: 302
Study 25798694 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG lasers
Number of subjects: 42
Study 25798694 — intervention group
Group type: COMPARATOR
Intervention: Cryotherapy
Number of subjects: 42
Study 23524720 — intervention group
Group type: EXPERIMENTAL
Intervention: Single peripheral nerve block using 1% lidocaine and betamethasone
Number of subjects: 60
Study 23524720 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nerve block)
Number of subjects: 60
Study 20812862 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentaerythritol tetranitrate (PETN) 80 mg orally two times per day for 14 days
Number of subjects: 36
Study 20812862 — intervention group
Group type: COMPARATOR
Intervention: Isosorbide dinitrate (ISDN) 40 mg retarded release orally two times per day for 14 days
Number of subjects: 36
Study 18608367 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous passive motion (CPM) and active exercises
Number of subjects: 63
Study 18608367 — intervention group
Group type: COMPARATOR
Intervention: Active exercises only
Number of subjects: 63
Study 18608367 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole group (both interventions)
Number of subjects: 63
Study 16981945 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical misoprostol
Number of subjects: 83
Study 16981945 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 15851226 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-3 cryothermia applications (n = 20)
Number of subjects: 40
Study 15851226 — intervention group
Group type: COMPARATOR
Intervention: Double-3 cryothermia applications (n = 20)
Number of subjects: 40
Study 15851226 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-3 cryothermia applications
Number of subjects: 40
Study 15851226 — intervention group
Group type: COMPARATOR
Intervention: Double-3 cryothermia applications
Number of subjects: 40
Study 10674537 — intervention group
Group type: EXPERIMENTAL
Intervention: Informational videotape (6 minutes duration)
Number of subjects: 198
Study 10674537 — intervention group
Group type: COMPARATOR
Intervention: Standard management (no videotape)
Number of subjects: 198
Study 9100216 — intervention group
Group type: EXPERIMENTAL
Intervention: Pear juice (fructose in excess to glucose and a large amount of sorbitol)
Number of subjects: 104
Study 9100216 — intervention group
Group type: EXPERIMENTAL
Intervention: Apple juice (similar to pear juice but contains four times less sorbitol)
Number of subjects: 104
Study 9100216 — intervention group
Group type: COMPARATOR
Intervention: White grape juice (equal amounts of fructose and glucose, sorbitol-free)
Number of subjects: 104
Study 9100216 — intervention group
Group type: COMPARATOR
Intervention: Purple grape juice (equal amounts of fructose and glucose, sorbitol-free)
Number of subjects: 104
Study 9100216 — intervention group
Group type: EXPERIMENTAL
Intervention: General outcome for pear juice
Number of subjects: 104
Study 9100216 — intervention group
Group type: EXPERIMENTAL
Intervention: General outcome for diarrhea
Number of subjects: 104
Study 8463768 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular coffee use
Number of subjects: 23
Study 8463768 — intervention group
Group type: COMPARATOR
Intervention: Caffeine-free diet
Number of subjects: 23
Study 2879782 — intervention group
Group type: EXPERIMENTAL
Intervention: Nizatidine 150 mg
Number of subjects: 10
Study 2879782 — intervention group
Group type: EXPERIMENTAL
Intervention: Nizatidine 300 mg
Number of subjects: 10
Study 2879782 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg
Number of subjects: 10
Study 2879782 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 800 mg
Number of subjects: 10
Study 2879782 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30882670 — intervention group
Group type: EXPERIMENTAL
Intervention: prasugrel/ticagrelor
Number of subjects: 3985
Study 30882670 — intervention group
Group type: COMPARATOR
Intervention: clopidogrel
Number of subjects: 3985
Study 28756943 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersive simulation of life-threatening events
Number of subjects: 48